2021年美国风湿病学会幼年特发性关节炎治疗指南:非药物治疗、药物监测、免疫接种与影像学推荐
该指南针对幼年特发性关节炎(JIA)所有表型,就非药物治疗、药物监测、免疫接种和影像学提出推荐。通过系统文献综述和GRADE方法评级证据质量,投票小组(含临床医生和患者/照护者)达成推荐方向和强度共识。所有推荐证据质量均为低或极低,超过半数推荐为条件性推荐。
要点
- 推荐物理治疗和职业治疗干预、健康均衡适龄饮食、特定药物实验室监测、广泛免疫接种及与患者/照护者共同决策。
- 所有推荐证据质量均为低或极低,超过半数推荐为条件性推荐。
- 指南补充2019年ACR JIA和葡萄膜炎指南及同期2021年指南,作为支持临床医生、患者和照护者决策的工具。
核心结论
- 该临床实践指南补充了2019年美国风湿病学会JIA和葡萄膜炎指南(涉及多关节炎、骶髂关节炎、附着点炎和葡萄膜炎)以及同期2021年关于少关节炎、颞下颌关节炎和全身型JIA的指南。
- 指南作为支持临床医生、患者和照护者决策的工具,推荐考虑关节和非关节表现的严重程度以及患者生活质量。
- 尽管证据通常为低质量且许多推荐为条件性推荐,但照护者和患者参与决策过程增强了指南的相关性和适用性;这些是推荐,临床决策应由治疗临床医生和患者/照护者做出。
研究设计与样本
- 制定机构为美国风湿病学会(American College of Rheumatology),方法包括开发临床相关的PICO问题、进行系统文献综述、使用GRADE方法对证据质量进行评级(高、中、低或极低),并由包括临床医生和患者/照护者的投票小组就推荐的方向(支持或反对)和强度(强或条件性)达成共识。
主要发现
- 所有推荐证据质量均评级为低或极低。
- 超过半数的推荐为条件性推荐。
关键数值与推荐
- 推荐包括使用物理治疗和职业治疗干预。
- 推荐健康、均衡、适龄饮食。
- 推荐特定药物实验室监测。
- 推荐广泛使用免疫接种。
- 推荐与患者/照护者共同决策。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有推荐证据质量均评级为低或极低。
- 超过半数的推荐为条件性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype. METHODS: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. RESULTS: Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. CONCLUSION: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
引用
- Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care Res (Hoboken). 2022. PMID: 35233989. doi:10.1002/acr.24839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。